+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Chronic Pancreatitis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

  • PDF Icon

    Report

  • 138 Pages
  • May 2024
  • Region: Global
  • IMARC Group
  • ID: 5969689
The 7 major chronic pancreatitis markets reached a value of US$ 1.7 Billion in 2023. Looking forward, the publisher expects the 7MM to reach US$ 2.4 Billion by 2034, exhibiting a growth rate (CAGR) of 3.91% during 2023-2034.

The chronic pancreatitis market has been comprehensively analyzed in this report titled "Chronic Pancreatitis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Chronic pancreatitis refers to long-term inflammation of the pancreas, a gland located behind the stomach. It is often characterized by the destruction and scarring of pancreatic tissue. Over time, this condition can impair the normal functioning of the pancreas, affecting its ability to produce digestive enzymes and hormones. The common symptoms associated with the ailment include pain in the upper abdomen, diarrhea, fatty, loose and pale stools, nausea, vomiting, shortness of breath, unexplained weight loss, excessive thirst, fatigue, etc. In severe cases, individuals suffering from this disease may also experience a yellowish discoloration in the eyes and skin, pancreatic fluids in the abdomen, internal bleeding, intestinal blockage, etc. The diagnosis of chronic pancreatitis typically involves a review of the patient's underlying symptoms, medical history, and imaging studies. Numerous procedures, including X-rays, ultrasounds, computed tomography scans, magnetic resonance imaging, etc., are adopted to identify abnormalities in the abdomen or check for any signs of inflammation in patients. The healthcare provider may also perform an endoscopy to directly visualize the condition of the pancreas and confirm a diagnosis.

The increasing incidence of prolonged and excessive alcohol intake, which can lead to inflammation and damage to the pancreas, is primarily driving the chronic pancreatitis market. Apart from this, the rising prevalence of gallstones, which can cause blockages in the pancreatic duct and prevent the normal flow of digestive enzymes, is also augmenting the market growth. Moreover, the widespread utilization of nonsteroidal anti-inflammatory drugs, opioids, analgesics, etc., for treating the disease, since they help in reducing the pain associated with the condition, is further creating a positive outlook for the market. Besides this, the inflating application of enzyme replacement therapy to significantly improve digestion and nutrient absorption in patients is also propelling the market growth. Furthermore, the escalating utilization of endoscopic retrograde cholangiopancreatography techniques that combine endoscopy and fluoroscopy to diagnose and treat conditions of the pancreatic duct is acting as another significant growth-inducing factor. Additionally, the emerging popularity of extracorporeal shock wave lithotripsy, a non-invasive procedure that uses shock waves to break down gallstones or pancreatic stones, thereby normalizing the functions of the pancreas, is expected to drive the chronic pancreatitis market in the coming years.

This report provides an exhaustive analysis of the chronic pancreatitis market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for chronic pancreatitis and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the chronic pancreatitis market in any manner.

Time Period of the Study

  • Base Year: 2023
  • Historical Period: 2018-2023
  • Market Forecast: 2024-2034

Countries Covered

  • United States
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Japan

Analysis Covered Across Each Country

  • Historical, current, and future epidemiology scenario
  • Historical, current, and future performance of the chronic pancreatitis market
  • Historical, current, and future performance of various therapeutic categories in the market
  • Sales of various drugs across the chronic pancreatitis market

Competitive Landscape:

This report also provides a detailed analysis of the current chronic pancreatitis marketed drugs and late-stage pipeline drugs.

In-Market Drugs

  • Drug Overview
  • Mechanism of Action
  • Regulatory Status
  • Clinical Trial Results
  • Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

  • Drug Overview
  • Mechanism of Action
  • Regulatory Status
  • Clinical Trial Results
  • Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

  • How has the chronic pancreatitis market performed so far and how will it perform in the coming years?
  • What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
  • What was the country-wise size of the chronic pancreatitis market across the seven major markets in 2023 and what will it look like in 2034?
  • What is the growth rate of the chronic pancreatitis market across the seven major markets and what will be the expected growth over the next ten years?
  • What are the key unmet needs in the market?

Epidemiology Insights

  • What is the number of prevalent cases (2018-2034) of chronic pancreatitis across the seven major markets?
  • What is the number of prevalent cases (2018-2034) of chronic pancreatitis by age across the seven major markets?
  • What is the number of prevalent cases (2018-2034) of chronic pancreatitis by gender across the seven major markets?
  • How many patients are diagnosed (2018-2034) with chronic pancreatitis across the seven major markets?
  • What is the size of the chronic pancreatitis patient pool (2018-2023) across the seven major markets?
  • What would be the forecasted patient pool (2024-2034) across the seven major markets?
  • What are the key factors driving the epidemiological trend of chronic pancreatitis?
  • What will be the growth rate of patients across the seven major markets?

Chronic Pancreatitis: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

  • What are the current marketed drugs and what are their market performance?
  • What are the key pipeline drugs and how are they expected to perform in the coming years?
  • How safe are the current marketed drugs and what are their efficacies?
  • How safe are the late-stage pipeline drugs and what are their efficacies?
  • What are the current treatment guidelines for chronic pancreatitis drugs across the seven major markets?
  • Who are the key companies in the market and what are their market shares?
  • What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the chronic pancreatitis market?
  • What are the key regulatory events related to the chronic pancreatitis market?
  • What is the structure of clinical trial landscape by status related to the chronic pancreatitis market?
  • What is the structure of clinical trial landscape by phase related to the chronic pancreatitis market?
  • What is the structure of clinical trial landscape by route of administration related to the chronic pancreatitis market?
This product will be updated with the latest data at the time of order. Consequently, dispatch time for this product will be 7-10 business days.

Table of Contents

1 Preface
2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 Executive Summary
4 Chronic Pancreatitis - Introduction
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 Chronic Pancreatitis - Disease Overview
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 Patient Journey
7 Chronic Pancreatitis - Epidemiology and Patient Population
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 Chronic Pancreatitis - Treatment Algorithm, Guidelines, and Medical Practices
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 Chronic Pancreatitis - Unmet Needs10 Chronic Pancreatitis - Key Endpoints of Treatment
11 Chronic Pancreatitis - Marketed Products
11.1 List of Chronic Pancreatitis Marketed Drugs Across the Top 7 Markets
11.1.1 Drug Name - Company Name
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Clinical Trial Results
11.1.1.4 Safety and Efficacy
11.1.1.5 Regulatory Status
Kindly note that the complete list of marketed drugs has been provided in the report.
12 Chronic Pancreatitis - Pipeline Drugs
12.1 List of Chronic Pancreatitis Pipeline Drugs Across the Top 7 Markets
12.1.1 NI03 - Kangen Pharmaceuticals, Inc
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 MS1819 SD- First Wave BioPharma/Mayoly-Spindler
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 CM6018 - CalciMedica
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. Chronic Pancreatitis - Attribute Analysis of Key Marketed and Pipeline Drugs
14. Chronic Pancreatitis - Clinical Trial Landscape
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 Chronic Pancreatitis - Market Scenario
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Chronic Pancreatitis - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Chronic Pancreatitis - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Chronic Pancreatitis - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Chronic Pancreatitis - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Chronic Pancreatitis - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Chronic Pancreatitis - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Chronic Pancreatitis - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Chronic Pancreatitis - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Chronic Pancreatitis - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Chronic Pancreatitis - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Chronic Pancreatitis - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Chronic Pancreatitis - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Chronic Pancreatitis - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Chronic Pancreatitis - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Chronic Pancreatitis - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Chronic Pancreatitis - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Chronic Pancreatitis - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Chronic Pancreatitis - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Chronic Pancreatitis - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Chronic Pancreatitis - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Chronic Pancreatitis - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Chronic Pancreatitis - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Chronic Pancreatitis - Access and Reimbursement Overview
16 Chronic Pancreatitis - Recent Events and Inputs From Key Opinion Leaders
17 Chronic Pancreatitis Market - SWOT Analysis
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 Chronic Pancreatitis Market - Strategic Recommendations19 Appendix

Methodology

Loading
LOADING...

Table Information